Opus Genetics, Inc. (IRD)
| Market Cap | 30.89M |
| Revenue (ttm) | 8.38M |
| Net Income (ttm) | -27.19M |
| Shares Out | 31.57M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399,127 |
| Open | 1.010 |
| Previous Close | 0.987 |
| Day's Range | 0.979 - 1.100 |
| 52-Week Range | 0.810 - 3.400 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+717.58%) |
| Earnings Date | Feb 15, 2025 |
About IRD
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II cl... [Read more]
Analyst Forecast
According to one analyst, the rating for IRD stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Gene...
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherite...